Orthopedic Spine Surgeon Dr Kingsley R Chin Unprecedented Impact On Pain Management With Record 16 Clinical Abstract Presentations at NANS 2022 Annual Meeting in Orlando

MALDEN, Mass., Jan. 10, 2022 /PRNewswire-PRWeb/ -- Dr. Kingsley R Chin is a graduate of Harvard Medical School and a professor and board-certified orthopedic spine surgeon who has been innovating and developing spine medical devices since 2000 with over 50 global patents issued to his name. In 2019 he made an unpopular and unimaginable decision to start training pain management doctors to perform outpatient minimally invasive spine surgeries on patients needing decompression for spinal stenosis and spinal fusions. "I knew orthopedic spine surgeons do not believe pain management physicians should be doing spinal fusions but I also knew pain management doctors were seeing a lot of patients who needed decompression, spinal fusions and sacroiliac joint fusions but were limited to pain medications, spinal cord stimulators and injections which were not treating the underlying mechanical problem.

I saw the opportunity to train pain management doctors to treat more patients so in 2019 I introduced them to percutaneous and fluoroscopic minimally invasive surgery techniques and devices which they quickly adopted and performed safely and effectively," said Dr Chin. "We have data on the efficacy of our interventional spine technologies for years in the hands of orthopedic spine surgeons and neurosurgeons so we only had to customize the techniques and instruments to make them more user-friendly to pain management doctors and focus on training," said Vito Lore, Vice President of Innovation at KICVentures Group. "It has become a passion for me to fly around the USA every week to train pain management doctors and see them gain confidence and belief when they see how much their patients have benefitted," said Angel Walker the lead Clinical Specialists and Trainer for KICVentures Group.

"This is validation for KICVentures Group and Dr Kingsley R Chin that their spine technologies are being adopted by us in pain management fairly rapidly and the major pain management societies are accepting the clinical evidence for presentation to us members led by NANS in 2022," said Dr Soubrata Raikar a leading pain management physician and key opinion leader presenting four abstracts at NANS.

It is a major break from tradition and a precedent to have an orthopedic spine surgeon attend a predominant pain management annual conference such as the NANS 2022 Annual Meeting. Eight abstracts will be presented on Inspan for patients who had spinal stenosis and degenerative disc disease who needed spinal fusion. Seven Abstracts will be presented on Sacrix results for treating patients with pain and sacroiliac joint dysfunction who successfully underwent a new percutaneous fluoroscopic lateral-oblique Sacrix SIJ fixation technique. There is one presentation on NanoFuse Biologics.

8 Inspan Accepted NANS Abstracts

• Lateral Spinous Process Displacement Correction By Interventional Pain Management Using An Interspinous Interlaminar Fixation Device - Darius Zagunis MD
• Stabilizing Grade 2 Degenerative Spondylolisthesis With Interspinous interlaminar fixation device by Pain Management physicians - Abdul Shahid MD
• Measuring Disc Height Increase After Interspinous Fixation Device In Patients Treated By Pain Management Physicians - Faris Abusharif MD
• Greater Than 6-month Follow-up Pain Management Doctor Experience With Interspinous Lumbar Fusion - Michael Esposito MD
• Interventional Pain Management Treatment Of Failed Spinal Cord Stimulator Using An Interspinous Interlaminar Fixation Device - Tian Xia MD, Soubrata Raikar MD
• Treating Spinal Stenosis using Interventional Interspinous Fixation - Fabio Pencle MBBS
• Awake Percutaneous Interspinous Lumbar Spinal Fusion Using IV Sedation And Local Anesthetic.Pain Management Experience - Soubrata Raikar MD
• Heterotopic Bone And Bursitis Associated With Use Of A Dynamic Interspinous Spacer - Faris Abusharif MD

7 Sacrix Accepted NANS Abstracts

• Spinal Cord Stimulator Batteries And Pain Pumps Placement In The Era Of Sacroiliac Fusion - Michael Rock MD
• CT Scan and Clinical Outcomes of Novel Lateral-Oblique Percutaneous SIJ Fixation - Fabio Pencle MBBS
• Interventional Fluoroscopic Sacroiliac Fusion in Patients with Failed Back Surgery Syndrome and Spinal Cord Stimulation - Gladstone McDowel MD
• Biomechanical Testing for Interventional Sacroiliac Joint Fixation Compression Screw - Fabio Pencle MBBS
• Greater Than 6-month Follow-up Pain Management Doctor Experience With Sacroiliac Joint Screw Fixation - Tian Xia MD
• Interventional Treatment Of Sacroiliac Joint Pain After Failed Back Surgery Using Percutaneous Lateral-Oblique Screw Technique - Tian Xia MD
• Innovative Awake Percutaneous Lateral-Oblique Sacroiliac Fusion Using IV Sedation And Local Anesthetic - Soubrata Raikar MD

1 NanoFuse Accepted NANS Abstracts

• Flowable NanoFuse Biologics Bioactive Glass And DBM Combination For Sacroiliac Joint Fusion: Interventional Spine Surgery    Fabio Pencle MBBS

About INSPAN, LLC
INSPAN, LLC is privately owned by the KICVentures Group and is focused on advancing the platform of patented interspinous fixation technology. The Inspan device has a proven ten-year track record with thousands implanted since FDA clearance in 2010. Indications for use includes spinal fusion and spinal stenosis.
https://www.MyInspan.com/

About SACRIX, LLC
Sacrix LLC is a KICVentures Group portfolio company focused on revolutionary percutaneous fluoroscopic lateral-oblique sacroiliac joint fusion technologies for the treatment of sacroiliac dysfunction and sacroiliitis. Sacrix developed its patented Sacrofuse threaded implant to be inserted percutaneously and received FDA clearance in 2015. The Gen1 Sacrofuse implant was compared head-to-head with market leader SI bone (SIBN) and found to have a 400% increase in pull-out strength. Sacrix has trained over 165 interventional pain physicians to perform its revolutionary percutaneous lateral-oblique sacroiliac joint fusion technique safely and effectively through a 1.5 cm incision minimally invasively in outpatient ambulatory surgery centers.
https://www.MySacrix.com

About NANOFUSE BIOLOGICS , LLC
NanoFuse Biologics is a world leader in synthetic biologics. NanoFuse is the only FDA-cleared combination of DBM and bioactive glass and is indicated for use in orthopedic surgery. NanoFuse Biologics is a KICVentures group portfolio company.
https://www.NanoFuseBiologics.com/

About KICVentures Group
Our founders have been investing in spine surgery since 2000, which makes us the most experienced healthcare investment holding company with the largest portfolio of medical device technologies focused on solutions for less invasive outpatient spine surgery. Our investment strategy is to acquire or invent disruptive technologies using our own capital or partner with private individual investors. This allows us the freedom to make quick and nimble decisions such as when we acquired AxioMed Viscoelastic Disc Technologies while other companies invested in spinal fusion.
https://www.KICVenturesGroup.com/

Investors
If you have any questions or comments, please contact us via email or phone, or send us a message using the contact form.
https://www.KICVenturesgroup.com/contact

Inspan is now indicated to be used for Spinal Stenosis and Fusion from T1-S1. The Inspan Spinous Process Plate System is a posterior non-pedicle supplemental fixation system intended for use in the non-cervical spine (T1-S1). It is intended for plate fixation/attachment to the spinous process for the purpose of achieving supplemental fusion for the following indications: spondylolisthesis, trauma (fracture or dislocation), tumor, or degenerative disc disease (defined as discogenic pain with degeneration of the disc confirmed by history and radiographic studies). The device is intended for use with bone graft material and is not intended for stand-alone use.

Media Contact

Aditya Humad, KICVentures Group, 267-342-3968, [email protected]

LinkedIn

SOURCE KICVentures Group